Terms ending in 2029
Every in-force patent on Abraxis Bioscience, LLC's record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,799,954 | Dicarbonyl Derivatives and Methods of Use In force · High confidence | Nantbioscience, Inc. | In force | High confidence | |
| US 8,003,402 | Method for Measuring the Concentration of a Glycosaminoglycan Anticoagulant In force · High confidence | Active Biomaterials LLC | In force | High confidence | |
| US 8,034,765 | Compositions and Methods for Preparation of Poorly Water Soluble Drugs with Increased Stability In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 8,821,836 | Sparc Binding Peptides and Uses Thereof In force · Low confidence | Abraxis BioScience, LLC | In force | Low confidence | |
| US 9,295,733 | Sparc Binding Scfvs In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence | |
| US 10,053,504 | Sparc Binding Scfvs In force · High confidence | Abraxis Bioscience, LLC | In force | High confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Abraxis Bioscience, LLC.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.